Abstract
Tumor-associated macrophages (TAMs) are a major component of the tumor immune microenvironment (TIME) and are associated with a poor prognostic factor in several cancers. TAMs promote tumor growth by facilitating immunosuppression, angiogenesis, and inflammation, and can promote tumor recurrence post-therapeutic intervention. Major TAM-targeted therapies include depletion, reprogramming, as well as disrupting the balance of macrophage recruitment and their effector functions. However, intervention-targeting macrophages have been challenging, since TAM populations are highly plastic and adaptation or resistance to these approaches often arise. Defining a roadmap of macrophage dynamics in the TIME related to tissue and tumor type could represent exploitable vulnerabilities related to their altered functions in cancer malignancy. Here, we review multiple macrophage-targeting strategies in brain, liver, and lung cancers, which all emerge in tissues rich in resident macrophages. We discuss the successes and failures of these therapeutic approaches as well as the potential of personalized macrophage-targeting treatments in combination therapies.
Introduction
The innate immune system, which consists of macrophages, dendritic cells, neutrophils, and a variety of other effector cells, is indispensable to mount rapid defense mechanisms in the context of homeostatic disruption (1). In the late nineteenth century, Élie Metchnikoff identified macrophages and their phagocytic activity (2), and since then, these cells have been singled out as key players in innate immunity and inflammation while being essential for tissue maintenance (3).
The past decades have emphasized the importance of investigating macrophages, since they not only are responsible for tissue homeostasis but also can contribute to the pathophysiology of several diseases including development and inflammatory disorders as well as cancer, depending on their activation phenotype (4).
For many years, tissue-resident macrophages were thought to originate from bone marrow-derived progenitors and blood monocyte intermediates that differentiate into mature cells once seeded into organs (5). However, the field of development biology has recently expanded our knowledge regarding tissue macrophage ontogeny. Several genetic tracing studies revealed that multiple macrophage populations develop from embryonic progenitors and are able to self-renew by local proliferation of mature, differentiated cells (6, 7).
Each tissue microenvironment shapes macrophage morphological and functional characteristics according to the homeostatic need of its local surrounding, suggesting that macrophage tissue-specific functions are not strictly dependent on their ontogeny and that the surrounding environment imprints macrophages locally (3). Additionally, several studies reported that macrophage functions are regulated epigenetically (8, 9).
This body of work, mainly performed in the course of development and homeostasis, raises the unanswered questions of macrophage phenotype adaptation in a tissue and ontogeny-specific manner in diseased conditions.
Macrophages present in the microenvironment of tumors are referred to as tumor-associated macrophages (TAMs) and are associated with a poor prognostic factor in several solid cancers (10–12). TAMs promote tumor growth by facilitating immunosuppression, angiogenesis, and inflammation, and can also affect tumor recurrence after conventional therapies (13). These characteristics, together with their genetically stable properties, have rendered macrophages attractive therapeutic targets in the tumor immune microenvironment (TIME) (12, 14). However, the high plasticity and versatility of TAMs, their distinct embryological origins, and their evolution within the TIME during cancer progression and treatment challenge their efficient targeting.
In this review, we build a roadmap of macrophage dynamics within multiple TIME, with a particular focus on tissue and tumor specificity. We will discuss the successes and failures of macrophage targeting with relation to TAM tissue and tumor specialized functions and propose how combinatorial targeting could be implemented to utilize the yet untapped vulnerabilities of these cells in cancer.
Macrophage Ontogeny and Education in Development and Homeostasis
Unlike most immune cells that originate from hematopoietic stem cells (HSCs), certain tissue-resident macrophages derive predominantly from embryonic progenitors, including yolk-sac macrophages and fetal liver monocytes (7, 15). The contribution of these two types of embryonic progenitors varies among different tissue-resident macrophage populations (7, 15).
The subset of resident macrophages in the central nervous system (CNS), referred to as microglia, are widely accepted to be the only tissue-resident macrophages exclusively originating from yolk sac-derived progenitors (16, 17). Embryonic microglia precursors emerge as early as E7.25 (17) and remain the sole source of macrophages in the adult brain parenchyma through their self-renewal potential.
Unlike microglia, Kupffer cells in the liver and alveolar macrophages in the lung are suggested to represent a mixed population of yolk sac macrophages and fetal liver monocytes (18). Kupffer cells and alveolar macrophages develop predominantly from erythro-myeloid progenitors (EMPs) in the yolk sac at E8.5, followed by their migration to the fetal liver by E10.5, which give rise to several cell types including fetal macrophages and monocytes (15). Fetal Kupffer cells are observed in the hepatic sinusoid at E11.0 in mouse embryos and express the macrophage marker F4/80+ (19), while alveolar macrophage differentiation begins with the distribution of fetal macrophages and fetal monocytes throughout the developing lung at around E12.5 and E16.5, respectively (20). Further differentiation of alveolar macrophages from fetal precursors continues until E18.5 and fully colonize the alveolar space during the first days after birth (20).
After birth, Kupffer cells and alveolar macrophages differentially rely on their potential for self-renewal and proliferation for their maintenance. While the pool of adult Kupffer cells is only marginally enriched by HSC-derived cells under steady state conditions (<5%), a substantial proportion of lung alveolar macrophages are progressively replaced during the normal aging process (7, 15).
To differentiate and maintain their tissue-specific functions, tissue-resident macrophages rely on specific growth factors and multiple transcription factors (21). Macrophage colony-stimulating factor-1 receptor pathway (CSF-1R, ligands M-CSF/IL-34) is a crucial signaling node mediating the maintenance of Kupffer cells and microglia (22, 23), while CSF-2R/GM-CSFR appears to be essential in alveolar macrophages differentiation (24). Engagement of the transcription factors (TFs) Pu.1, Irf8, Runx1, and SMAD regulate the development of microglia (Figure 1) (17, 23, 25, 26), while myeloid TFs such as Myb, Id2, Batf3, and Klf4 are not required for microglia development (7, 17). Id2 and Id3 TFs are, however, essential to generate and maintain Langerhans cells and Kupffer cells, respectively (27, 28). Differentiation and maintenance of alveolar macrophages are dependent on transforming growth factor-β receptor (TGF-βR) signaling through the upregulation of PPAR-α (29, 30), and TGF-β is a master regulator of microglia development (Figure 1) (21, 29).
Figure 1
Further changes in macrophage marker expression profile occur postnatally, which distinguish them from their precursors and other tissue-resident macrophages. Tim4 is maintained throughout development and postnatally in Kupffer cells, but lost in lung alveolar macrophages and brain microglia (28). Postnatal molecular signatures indicated tissue-specific expression of the TFs Sall1 (26) and Sall3 in microglia and Nr1h3 (Lxra) in Kupffer cells (Figure 1) (28). Molecular signatures of alveolar macrophages revealed important postnatal changes in gene expression, which might be related to their location at epithelial barriers (28). Those signatures showed for example, tissue-specific expression of the TF Pparg in alveolar macrophages (28).
Altogether, ample evidence supports the concept that once differentiated, each tissue-resident population of macrophages is distinct in their molecular profiles in a manner that is dependent on their embryological origin and specialized tissue education.
Tissue-Specific Functions of Resident Macrophages
Each tissue microenvironment necessitates macrophages to undertake specific functions to maintain their physiological role in the body homeostasis. Consequently, tissue-resident macrophages adopt morphological and functional characteristics depending on their local surroundings. Unlike Kupffer cells in the liver or alveolar macrophages in the lung, microglia are the sole myeloid cells present within the healthy brain parenchyma, due to their unique ontogeny and seclusion from the peripheral circulation by the blood–brain barrier (BBB) (31). Microglia regulate the CNS homeostasis through phagocytic clearance of apoptotic neurons (32), regulation of neuronal survival, neurogenesis, and oligodendrogenesis by secreting various neurotrophic factors, including insulin-like growth factor 1 (IGF-1), IL-6, IL-1β,TNF-α, and IFN-α (33–35). Furthermore, microglia are essential in maintaining and remodeling the synaptic network (36). Synaptic pruning includes elimination of undesired synapses, which is mediated by TGF-β signaling and expression of the complement protein C3 (37).
Tissue-resident Kupffer cells mediate the tolerogenic environment of the liver and are important effectors in maintaining tissue and systemic homeostasis (38). Kupffer cells are involved in the clearance of bacteria and microbial products including pathogen-associated molecular patterns (PAMPs), damaged erythrocytes, haptoglobin–hemoglobin complexes and erythrocyte-derived hemoglobin-containing vesicles from the blood. These pleiotropic functions of liver Kupffer cells are mediated by expression of multiple Toll-like receptors (TLRs), Fc receptors, and specific scavenger receptors including SR-A (CD204), MARCO (39), and CD163 (40).
Alveolar macrophage functions are regulated by the surrounding airway epithelium through their interactions with CD200-expressing alveolar epithelial cells in the presence of TGFβ and IL-10. They are involved in surfactant lipid metabolism (41) and multiple cytokine production through the induction of PPAR-α by CSF-2 (GM-CSF) (3, 30).
Kupffer cells and alveolar macrophages have the ability to promote the suppressive activity of regulatory T cells (Tregs) by producing IL-10 (42), TGF-β, or retinoic acid (43, 44), thus leading to effector T cell immunosuppression. Alveolar macrophages additionally induce T cell antigen-specific unresponsiveness, promoting tolerance to innocuous antigens to prevent unnecessary inflammatory responses (45).
Under physiological conditions, the potential of tissue-resident macrophage self-renewal and proliferation is poorly understood. Both metabolic and nutritional signals have been suggested to regulate macrophage self-renewal (46). Similarly, the Th2 cytokine IL-4 promotes macrophage self-renewal during inflammation (47). Because these different signals are generally altered or upregulated in the course of tumorigenesis, they could favor the selective proliferation of tumor-educated, tissue-resident TAM subsets, thus fueling their pro-tumorigenic participation to the growing tumor. In that case, specific targeting of proliferative tissue-resident TAMs could represent a tantalizing therapeutic avenue to be applied early on in the course of tumorigenesis.
TIME Shaping in Solid Tumors
The TIME consists of a large variety of immune cells with distinctive composition and functions that differ greatly between, but also within, cancer types (14, 48). Immune cells are highly heterogeneous and can exert both anti- as well as pro-tumorigenic activities depending on environmental signals they are exposed to, including inflammation and tumor cell genetic make-up.
Wide-ranging immunogenomic analysis of more than 10,000 tumors comprising 33 distinct cancer types were classified in six different immune content patterns, spanning cancer tissue types, and molecular subtypes (49). This recent study identified that several tumors, including glioma and hepatocellular carcinoma (HCC), displayed a greater range in leukocyte fraction compared to other cancer types. The immune landscape in these tumors displayed a more prominent M2-like macrophage signature, suppression of Th1 cell activation, and a high anti-inflammatory macrophage response. Lower-grade gliomas showed the lowest lymphocyte and highest macrophage responses, dominated by anti-inflammatory, M1-like macrophages (49). On the other hand, IDH1 mutations (also found in gliomas) correlated with low immune cell infiltration (50) and decreased leukocyte chemotaxis, resulting in fewer tumor-associated immune cells and were associated with better clinical outcome (49). Lung squamous cell carcinoma exhibited a “wound healing” immune subtype activation with elevated angiogenesis-associated genes, a high proliferation rate, and a Th2 cell bias in the adaptive immune infiltrate (49). However, these immunogenic analyses only partly integrated the tumor's genetics, and it has now been reported that deregulation of several cancer cell-intrinsic pathways influences the inflammatory TIME (48). Indeed, a few examples of how the genetic make-up of cancers affects tumor immunity have been highlighted in recent years. Expression of the tumor suppressor gene p53 together with NF-kB stimulate senescence and a senescence-associated secretory phenotype (SASP) in hepatic stellate cells, which subsequently induced a tumor-inhibiting phenotype in macrophages. Loss of p53, on the other hand, induced the activation of macrophages toward a tumor-promoting phenotype and fueled inflammation-induced HCC (48, 51). NF-kB activity was increased upon loss of p53, which promoted tumor development in the KrasLSL−G12D/+; Trp53F/F lung adenocarcinoma model, while NF-kB inactivation resulted in increased immune cell influx and impaired lung cancer formation (52). Moreover, MYC amplification resulted in increased expression of IL-23 and CCL9 by tumor cells in lung adenocarcinoma murine models, which led to a rapid decrease of B, T, and NK cells, while macrophages were increasingly recruited and activated in the TIME (53). Myc activation has also been shown to mediate and maintain the transition from indolent pancreatic lesions (PanIN) to full adenocarcinoma (PDAC), by triggering the inflammatory ensemble of cell types characteristic of aggressive lesions. The reshaping of the PanIN TIME to a PDAC phenotype was dependent on early recruitment of macrophages through CCL9 and CCL2, and fully reversible in PDAC when Myc activity was blocked or deleted, with rapid TAM and neutrophil efflux (54). Deletion or mutations of the tumor suppressor p53 in murine models of triple-negative breast cancer have recently been reported to enhance neutrophilic inflammation, which is mediated by tumor cell production of WNT ligands promoting the secretion of IL-1β by TAMs (55, 56). Similar results were obtained in prostate cancer models where both Ly6C+ monocyte and Ly6G+ neutrophil recruitment was blocked, giving rise to tumor growth control specifically in pTEN and p53 double KO mice (57). These studies pioneered the concept of personalized immunomodulation of innate cells, in this case targeting neutrophils in p53-altered breast and prostate cancers. Such cancer cell genetics-guided approaches to target TAMs have not yet been explored, and could represent potent therapeutic strategies given the abundance of TAMs in multiple solid tumors. However, they also may be complicated by both TAM cell plasticity and ontogeny, highlighting the need for uncovering the dynamics of these cells in a mutational status-dependent manner.
Altogether, these reports emphasize the influence of tumor cell genetics on immune subset recruitment and activation, suggesting that tumors shape their local TIME to their advantage, which could constitute a potential vulnerability to exploit in cancer immune-modulation therapy.
Ambivalent Role of TAM Along Tumorigenic Progression
Several studies explored the dual roles of TAMs in tumor progression of different cancer types (58). Depending on environmental stimuli, TAMs can initiate both pro-inflammatory as well as anti-inflammatory responses through their ability to directly suppress or promote the cytotoxic functions of natural killer (NK) cells and CD8+ T cells, or by triggering Th1 immune response and cytotoxic activity toward cancer cells via toxic intermediates production such as NO and ROS (59).
In grade IV gliomas (glioblastoma: GBM), both microglia and monocyte-derived macrophages (ontogenetically different macrophage subsets) contribute to the TAM pool and influence tumor malignancy (60). Among the non-neoplastic cells in the GBM TIME, TAMs account for 30–40% of the total GBM tumor mass, suggesting their importance in tumor maintenance and immunosuppressive features of these aggressive tumors (61). Interestingly, the density of TAMs is lower in grade II and III gliomas, in which they do not display the M2-like phenotype characteristic of grade IV tumors (62). Acquisition of this protumorigenic features in GBM relies on multiple signaling molecules promoting the M2-like polarization of TAMs, as M-CSF (CSF-1) (63).
The role of TAMs in lung cancer progression remains controversial, potentially due to different populations of macrophages analyzed in multiple tumor settings (64–67). Several reports suggest a positive correlation between TAM infiltration and favorable prognosis. Higher tumor islet densities of pro-inflammatory macrophages were associated with extended survival in non-small cell lung cancer (NSCLC), while the presence of interstitial macrophages correlated with reduced survival (66, 68). Immunostaining using CD68/iNOS (markers for pro-inflammatory macrophages) and CD68/CD163 (markers for anti-inflammatory macrophages) supported these findings with high infiltration of pro-inflammatory macrophages in the tumor islets together with low infiltration of anti-inflammatory TAMs being associated with improved NSCLC patients' survival (69). However, studies also show substantial evidence that TAMs correlate with poor prognosis in human lung cancer (70, 71). For instance, TAMs are associated with tumor IL-8 mRNA expression and increased intratumoral microvasculature, which correlates negatively with survival (70).
In the liver TIME, pro-inflammatory TAMs and endothelial cells produce TNF-α, which activates NF-κB and subsequently protects hepatocytes from apoptosis (72). However, exposure to IL-4, IL-10, and IL-13 triggers a switch toward an anti-inflammatory phenotype and the release of TGF-β, Arg1, and IL-10, as well as factors that promote tissue remodeling and angiogenesis, including VEGF, PDGF, MMP2, MMP9, and MT1-MMP (59, 73–75). Moreover, anti-inflammatory TAMs induce S100A8 and S100A9 expression on HCC cancer cells (76), release CCL22 and epidermal growth factor (EGF) to recruit Treg cells, and promote migration of tumor cells, altogether contributing to HCC malignancy and liver metastasis (Figure 2) (77). The role of M2-like TAMs in facilitating the epithelial–mesenchymal transition (EMT) of HCC cells in a TLR4/STAT3 signaling-dependent manner further supports the notion that these cells promote liver cancer malignancies (78).
Figure 2
Overall, it is now generally accepted that anti-inflammatory TAMs are mainly associated with poor survival while pro-inflammatory macrophage infiltration tends to correlate with better outcome (64–67, 70). However, limited studies have distinguished tissue-resident macrophages from monocyte-derived macrophages within solid tumors. This distinction is particularly puzzling in macrophage-rich organs like the brain, lung, and liver. In light of recent results showing that macrophage progenitors are seeded early in these organs, it is of high interest to determine the extent of resident macrophages contributing to the TAM pool and subsequently to pro- or anti-inflammatory cells, or whether they are replaced by recruited monocytes in the course of tumorigenesis.
TAM Recruitment and Activation Within the Lung, Liver, and Brain TIME
During early tumor lesions, TAMs are recruited in the TIME through multiple secreted factors, and can in turn release several cytokines, chemokines, and growth factors that fuel tumor progression (Figure 2).
The generation of an immunosuppressive, pro-tumorigenic TIME in which macrophages are one of the most abundant immune cell players is often a consequence of chronic inflammation and organ injury (79). In the lung, inhalation of particulate matter (PM) or cigarette smoke causes activation of alveolar macrophages via cell surface receptors, including TLRs, MARCO, or S-RA. Activated alveolar macrophages release a variety of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, as well as IL-8 and GM-CSF (80), which promote tissue injury and recruitment of additional immune cells. Small cell lung cancer cells display high levels of monocyte chemoattractant protein-1 (MCP-1, also known as CCL2), which leads to increased recruitment of blood monocytes to tumors (Figure 2C) (81). Increased expression of IL-23 and CCL9 by tumor cells additionally promotes recruitment and activation of macrophages in the KrasG12D-driven lung adenocarcinoma model upon MYC amplification, as mentioned in the previous paragraph (53).
When tissue injuries cannot be resolved, chronic liver diseases such as non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), chronic HBV, or HCV infection lead to hepatic fibrosis and cirrhosis, which eventually can favor the development of hepatocellular carcinoma (HCC) (38). Resident Kupffer cells are rapidly activated by various danger-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs) in that context, including lipopolysaccharide (LPS), viral RNA, DNA fragments, free fatty acids, uric acid, and ATP, sensed by multiple TLRs and P2X purinoreceptor 7 (P2X7), respectively (82). Activation of Kupffer cells leads to inflammasome formation and the subsequent release of various pro-inflammatory cytokines such as IL-1β, which contribute to hepatic injury (83). Kupffer cells, hepatocytes, and stellate cells also secrete chemokines, including CC-chemokine ligand 1 (CCL1), CCL2, and CX3CL1, that promote the extensive recruitment of bone-marrow-derived monocytes into the liver (38), where they differentiate into monocyte-derived macrophages (Figure 2A). During early tumor lesions, TAMs are recruited in a HCC environment mainly via CSF-1, CCL2, VEGF, and TGF-β, and in turn release additional cytokines, chemokines, and growth factors that promote HCC progression (59).
While high immune cell influx to sites of injury is easily achieved in the liver or in the lung, the healthy brain parenchyma is secluded from circulation by the BBB and microglia are the only myeloid cells due to their early seeding during development and specific ontogeny (31). Microglia become activated in response to early tumor stimuli, such as IL-6, TGF-β, prostaglandin E2 (PGE2), ATP, and miRNAs, which leads to the release of various cytokines, growth factors, and MMPs (84). Tumor cells, in turn, release additional mediators that will further recruit and promote another wave of microglial activation, resulting in a cyclic process in GBM, known as reactive microgliosis (Figure 2B) (84). Activated microglia switch from a resting state toward an amoeboid phenotype and subsequently release several factors that promote glioma proliferation and migration, including stress-inducible protein 1 (STI1), epidermal growth factor (EGF), TGF-β, as well as IL-1β, which modulate the BBB to further allow invasion of peripheral immune cells into the CNS (85, 86). Complementing the pool of microglia in the brain TIME, monocyte-derived macrophage recruitment is in part mediated by CSF-1, ATP, glial cell-derived neurotrophic factor (GDNF), GM-CSF, CCL2, CX3CL1, and, especially in hypoxic areas, CXCL12 (SDF-1) (61, 63, 85, 87–90). Tumor-secreted CCL2 signals through the CCR2 receptor expressed on TAMs and result in release of IL-6 to promote glioma cell invasiveness (91). In addition to bulk, differentiated glioma cells, glioma stem-like cells (GSCs) have been reported to reside in GBM perivascular niches and to be resistant to radiation and chemotherapy (92). GSCs enhance macrophage recruitment from the periphery by producing chemoattractants, such as periostin (93). Recruited TAMs can in turn influence GSCs by releasing TGF-β followed by production of MMP-9, promoting GSC invasiveness (94).
Distinguishing Macrophage Subsets in Lung, Liver, and Brain Cancers
Macrophage populations are highly plastic and adapt their phenotype in response to microenvironmental influences (95); however, the differential responses to inflammation and tumorigenic progression in the recruited vs. resident macrophage populations is still unclear.
The challenge in distinguishing subpopulations of TAMs resides in the ability of monocyte-derived macrophages to acquire some of the tissue-resident macrophage marker expression and functionality in the course of tissue injury and tumorigenesis.
Several studies suggest that TAMs in lung tumors are largely monocyte-derived (2). During lung injury/fibrosis, resident alveolar macrophages are identified as CD64+CD11c+F4/80+MerTK+SiglecFhigh, while monocyte-derived alveolar macrophages are characterized as CD64+CD11c+F4/80+MerTK+SiglecFlow (96). In the KrasLSL−G12D/+p53fl/fl lung tumor model, fluorescently labeled monocyte precursors differentiate into macrophages in developing tumors (97). Similarly, in the Lewis lung carcinoma (LLC) model of NSCLC, tracing of labeled monocyte progeny demonstrated that Ly6Chi monocytes exclusively differentiate into two main TAM populations: MHC-IIlo anti-inflammatory and MHC-IIhi pro-inflammatory TAMs (98). Although both TAM subsets are derived from a common Ly6Chi monocyte precursor, MHC-IIlo TAMs are found in hypoxic regions and upregulate hypoxia-regulated genes, such as VEGF-A, GLUT-3, GLUT-1, and iNOS, and acquire pro-angiogenic functions (98). However, a limited number of macrophage lineage tracing approaches interrogating their embryological origins have been undertaken in the context of lung tumors, thus restricting our understanding of the TAM pool composition and ontogeny-dependent functions in this disease (99).
Hepatic macrophage populations are highly plastic and adapt their phenotype in response to microenvironmental influences (95). Flow cytometry analysis identified that inflammatory monocyte-derived macrophages express high levels of Ly6C and CCR2 and are able to rapidly infiltrate tissue upon injury. Anti-inflammatory monocyte-derived macrophages, on the other hand, are Ly6Clow, express high levels of CX3CR1, and exhibit a patrolling behavior along the liver vasculature (74). Resident Kupffer cells are F4/80+Clec4F+Tim4+ macrophages and negative for the marker Ly6C (15, 100). This distinction, despite being oversimplified, has been the basis for the handful of studies examining the ontogeny of macrophages in liver injury and tumorigenesis.
In injured livers, bone marrow-derived macrophages (BMDMs) were equally capable of responding to LPS and parasitic insults compared to tissue-resident Kupffer cells (KCs) (101). However, KCs were more effective at accumulating acetylated low-density lipoprotein, while BMDM uptake of a larger range of bacterial pathogens (101). KCs are the first macrophage population to respond to newly formed tumor signals and are therefore involved in HCC onset (102), while BMDMs are essential during later disease progression stages and metastasis formation (103). During HCC progression, monocyte-derived macrophages suppress the functions of effector T and B cells through expression of the immune-checkpoint molecule PD-L1 and the immunosuppressive cytokine IL-10, and are able to directly inhibit NK cells and CD8+ T cells (104). Infiltrating monocytes/macrophages lead to upregulation of S100A8 and S100A9 expression in cancer cells, which was correlated with elevated metastasis formation in HCC (76). While these recent studies shed light into the relative contribution of KC or monocyte-derived macrophages to tumor progression, the extent to which these populations are functionally and transcriptionally distinct in the course of cancer malignancy remains to be fully addressed using lineage tracing tools, as they have now been developed to examine liver macrophage homeostatic functions (100, 105).
The influence of macrophage ontogeny on brain tumor development has been the subject of thorough studies in recent years, significantly enhancing our understanding of the role of macrophage origin in this organ compared to lung or liver cancer. Traditionally, CD45 expression was used to differentiate resident microglia (MG; CD45low) from monocyte-derived, infiltrating BMDMs (CD45high) (106). Irradiation chimera experiments (where murine heads were protected from irradiation to avoid disruption of BBB) demonstrated that the main source of TAMs in primary brain tumors are resident MG, which showed an upregulation of CD45 expression in gliomas (107, 108). However, these findings were challenged by a recent study employing Cx3cr1 and Ccr2 double transgenic lineage tracing knock-in mice models, showing that recruited Cx3cr1loCcr2hi monocytes differentiated into Cx3cr1hiCcr2lo macrophages and Cx3cr1hiCcr2− microglia-like cells in glioblastoma. In this study, infiltrating BMDMs represented ~85% of the total TAM population, while resident MG accounted for only the rest (109). However, using bone marrow chimera experiments and multiple lineage tracing glioma mouse models, Bowman et al. reported that MG and BMDM content was strikingly different, closer to 60 and 40%, respectively. The identification of Itga4 (Cd49d) as a monocyte-derived macrophage-specific marker in multiple brain malignancies further confirmed these results in glioma patient samples.
While these different results may be explained by the different lineage tracing methods employed, glioma genetics or the choice of surface markers distinguishing MG and BMDMs, they all confirmed that monocyte-derived macrophages are indeed recruited to the brain TIME. Further analyses of these distinct TAM subsets revealed that glioma MG were enriched for the classical complement components C4b, C2, and pro-inflammatory cytokines such as Ccl4 and TNF-α, while BMDMs were enriched immune effectors, such as Cd40, Tlr11, Tlr5, Tlr8, Jak2, and “wound healing” chemokines, including Ccl22, Ccl17, Cxcl2, Cxcl3, and Cxcl16. These distinct signatures remain to be functionally tested and their relevance in human GBM remains to be determined. Nevertheless, the transcriptional programs specific to each macrophage subset in primary brain tumors underline their ability to distinctively respond to tumor progression.
Monotherapies Targeting Macrophages in vivo
As mentioned above, numerous studies have shown substantial evidence that TAMs contribute to tumor progression and are associated with poor prognosis in solid cancers (10, 11). Major approaches targeting these cells within the TIME include macrophage depletion, macrophage reprogramming, and macrophage recruitment blockade (13, 110). However, successful macrophage-targeting strategies have been challenging to successfully implement, due to TAM high plasticity, thus giving rise to therapy resistance (110). Moreover, the vast majority of these therapeutic approaches currently target TAMs as a whole population, without fully considering their ontogeny or phenotype evolution within solid tumors.
Targeting of TAMs that have acquired protumorigenic functions presents the advantage of eliminating cells that are fueling tumor progression while preserving macrophages that may have retained their physiological, anti-tumor functions. Thus, specific depletion of M2-like TAMs is therapeutically interesting, albeit difficult to achieve. The scavenging receptor CD163, is a well-accepted marker of M2-like TAMs, and has been shown to promote their protumorigenic roles in murine and human settings (111). Genetic or nanoparticle-mediated ablation of CD163+ TAMs in melanoma leads to sustained tumor regression, partly through cytotoxic T lymphocyte recruitment and activation (112).
One of the main survival and differentiation cytokines critical to TAM biology is CSF-1, whose downstream signaling pathway can be blocked by targeting its receptor CSF-1R (113). Depending on the cancer type, blockade of CSF-1R signaling showed variable outcomes. CSF-1R blockade using the receptor tyrosine kinase (RTK) small drug inhibitor BLZ945 (Novartis) limits glioma progression and leads to regression of established tumors (114). Mechanistically, CSF-1R inhibition mediated the reprogramming of TAMs toward an anti-tumorigenic phenotype, without depleting cells within the tumor bulk (114, 115). However, long-term exposure to CSF-1R inhibition as a monotherapy was found associated with PI3K hyper-activation driven by IGF-1 production in the TIME (115). Although the CSF-1R inhibitor PLX3397 showed anti-tumor efficacy in a pre-clinical glioma model (63), these findings were not translated in recurrent glioblastoma patients (116). Human glioblastoma frequently bear alterations of PI3K and PTEN (117), which might be associated with inherent resistance to CSF-1R targeting, readily explaining the results of this clinical trial. These results underline the importance of identifying the acquired resistance to long-term macrophage targeting and consequently adapt treatment in a personalized manner, similarly to what has been done for targeted therapies (110).
The effect of CSF-1R targeting was strikingly different in breast and in cervical pre-clinical murine models. CSF-1R inhibition led to macrophage depletion, thereby causing increased infiltration of CD8+ cytotoxic T cells and improving responses to chemotherapy and radiotherapy (10, 118, 119). Thus, CSF1-R targeting leads to different consequences in the TIME, causing either depletion or macrophage reprogramming in a tumor-specific manner. It is yet to be determined whether blockade of CSF-1R affects predominantly tissue-resident or recruited macrophages in solid tumors. In inflammatory models however, CSF-1R blockade mediated depletion of tissue-resident macrophages, which resulted in enhanced recruitment of pro-inflammatory monocytes. These results support the hypothesis that continuous CSF-1R inhibition would then be needed to behold therapeutic effects, as tissue-resident cell depletion could be compensated by recruitment of macrophage progenitors to replenish the pool of tissue/tumor-associated macrophages (120).
Another approach to limiting macrophage pro-tumorigenic roles in the TIME is to prevent their recruitment by inhibiting the chemokine gradients' axes they rely on, including Cxcl12 (SDF-1)/Cxcr4. Blocking Cxcr4 using the inhibitor AMD3100 resulted in reduced metastatic properties of mammary tumors (121). In metastatic melanoma, Cxcl12 favors monocyte differentiation into perivascular macrophages, thus enabling the establishment of an autocrine CXL12/CXCR4 loop promoting further leucocyte infiltration and metastatic progression (122). Tumor cell-secreted CCL2 also acts as a monocyte-attracting chemokine to recruit myeloid cells in several metastatic niches (123). Blockade of the CCL2/CCR2 axis led to reduction of monocyte infiltration in multiple TIME (124) and inhibits breast cancer cell metastatic seeding (123, 125). However, cessation of this CCL2/CCR2 blockade can lead to compensatory phenotype associated with increased breast cancer metastasis, for instance (126).
Several clinical trials are currently testing CSF-1/CSF-1R targeting agents (including the Novartis small-molecule inhibitor BLZ945 and Roche monoclonal antibody RG7155) in, among others, breast cancer, glioma, melanoma, ovarian cancer, and lung cancer (Table 1) (132). So far, only RG7155 has yielded therapeutically beneficial outcomes as a single agent in diffuse-type giant cell tumors patients and has been shown to deplete CSF-1R+CD163+ macrophages (113). CCR2 inhibitors (MLN1202 and PF-04136309) are utilized for their ability to reduce bone marrow-derived cell recruitment in metastatic cancers and as first-line treatment in pancreatic tumors (Table 1).
Table 1
| Company | Drug | Targets | Phase | References |
|---|---|---|---|---|
| MONOTHERAPY | ||||
| Novartis | BLZ945 | CSF-1R Advanced Solid tumors | I/II | In progress NCT02829723 |
| Roche | RG7155 | CSF-1R Locally advanced and/or metastatic ovarian and breast carcinoma | I | In progress NCT01494688 |
| Southwest oncology group | MLN1202 | CCR2 Bone metastasis | I/II | In progress NCT01015560 |
| Pfizer | PF-04136309 | CCR2 First-line metastatic pancreatic cancers | I/II | Terminated NCT02732938 |
| Sorafenib | VEGFR, PDGFR | III | (127) | |
| Bayer | Regorafenib | VEGFR1-3,PDGFRβ, FGFR Hepatocellular carcinoma | III | (128) |
| Centocor | CNTO888 | CCL2 Castration-resistant prostate cancer | II | (129) |
| COMBINATION WITH IMMUNOTHERAPY | ||||
| CP870893 + taxol/carboplatin | CD40 Metastatic melanoma | I | (130) | |
| BLZ945 + PRD001 | CSF-1 PD-1 Advanced solid tumors | I/II | In progress NCT02829723 | |
| LY3022855 + Tremelimumab | CSF-1R CTLA-4 Advanced solid tumors | I | In progress NCT02718911 | |
| COMBINATION WITH CHEMOTHERAPY | ||||
| Plexxicon | PLX3397 + Temozolomide | CSF1R, KIT, FLT3 Advanced solid tumors | I/II | In progress NCT01525602 |
| Pfizer | PF-04136309 FOLFIRINOX | CCR2 Advanced pancreatic adenocarcinoma | I/II | In progress NCT01413022 |
| Centocor | CNTO888+ Docetaxel Gemcitabine Paclitaxel+Carboplatin Doxorubicin | CCL2 Advanced solid tumors | II | (131) |
| COMBINATION WITH RADIOTHERAPY | ||||
| Plexxicon | PLX-3397 | CSF1R, KIT, FLT3 Primary glioblastoma | I/II | In progress NCT01790503 |
Summary of recent clinical trials using macrophage-targeting therapies.
Combination (Pre-) Clinical Therapies of Macrophage Targeting With Cytotoxic and Immunotherapy Agents
It is only in recent years that strategies using macrophage-targeting agents have been combined with targeted therapies, standard of care treatment or immunotherapies, revealing the potential of these approaches in solid tumors.
Combination of CSF-1R targeting with other RTK inhibitors showed enhanced treatment outcomes in several studies (133, 134). PLX3397 combined with the mTOR inhibitor rapamycin inhibits outgrowth of malignant peripheral nerve sheath tumors when compared to single drug treatment (133). In glioma, when combined with the multi-targeted kinase inhibitors vatalanib and dovitinib, PLX3397 did not induce depletion but depolarization of pro-tumorigenic TAMs and resulted in pronounced glioma regression (135). Moreover, both TAM reprogramming and depletion of TIE2-expressing macrophages (TEMs) together with VEGF ligand inhibition showed anti-tumor effect in orthotopic glioma models (136). In pre-clinical melanoma models, treatment with CSF-1R inhibitors enhanced the efficacy of the BRAF inhibitor vemurafenib, which was associated with depleted macrophages, allowing increased anti-tumorigenic CD8+ cytotoxic T cell infiltration (134).
The efficacy of CSF-1R inhibitors when concurrently administered with chemotherapy has also been reported. TAMs suppress the cytotoxic activity of antimitotic agents, including taxol, in breast cancer and promote early mitotic slippage (137). Mechanistically, TAM depletion favors increased levels of cancer cell-DNA damage and cell death in response to taxol, thus enhancing the response to this chemotherapy (137). Moreover, the combination of PLX3397 with the chemotherapeutic drug temozolomide and radiotherapy (NCT01790503) are currently assessed in phase 1b/2 study (18). Immune-cold tumors, such as pancreatic ductal adenocarcinoma (PDA), lack robust T cell infiltrates and are resistant to chemotherapy (138). Targeting TAMs in these types of tumors have thus been tested in order to lessen immunosuppression. Stimulation of the CD40 receptor at the cell surface of macrophages using agonistic CD40 antibody promotes clonal T cell expansion and combination treatment with chemotherapy resulted in optimized myeloid activation and T cell function (138). These results led to the development of a phase I study in which the agonistic CD40 antibody CP870893 (Pfizer) was combined with carboplatin and Taxol, confirming the safety of this treatment regimen (139). Clinical trials in which CSF1R inhibitors are combined with immunotherapy are currently ongoing, such as BLZ945 with PRD001 [monoclonal antibody targeting programmed cell death-1 (PD1)] and LY3022855 with tremelimumab [monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)] in advanced solid tumors (140).
Components of the TIME have pivotal roles in determining treatment outcomes of radiotherapy (RT) (141). RT leads to increased T cell recruitment to the TIME and can prime the immune system against cancer cells via immunogenic cell death (ICD). However, enhanced actions of suppressive immune cells such as TAMs constrain the efficacy of RT. TAMs are highly radioresistant and produce increased levels of Arg-1, COX-2, and iNOS post-irradiation, which promote early tumor regrowth (142). Meng et al. administered clodronate liposomes systemically or locally before RT, to deplete circulating and resident TAMs, which increased the anti-tumorigenic effects of ionizing radiation (143). Inhibition of CSF-1R using PLX3397 delays recurrence of GBM after ionizing radiation by altering myeloid cell recruitment and polarization (144). RT also causes increased TNF-α-induced VEGF ligand production by TAMs and VEGF-neutralizing antibodies enhanced the anti-tumor efficacy to RT (143). In PDAC, RT leads to the production of CCL2, which recruits macrophages to tumor sites to support tumor proliferation and neo-angiogenesis after RT. Therefore, disrupting the CCL2–CCR2 axis in combination with RT may improve RT efficacy in PDAC (145).
Personalized Approaches Targeting Macrophages
Personalized macrophage targeting, tailored-based on tissue and tumor types, could represent a significant advance in the development of effective and long-lasting treatments. However, as mentioned in the previous section, more knowledge is needed to take on these approaches, and multiple tumor cell-intrinsic and extrinsic factors should be considered with regard to TAM immunomodulation (146).
High-throughput analysis of GBM samples shows that many types of mutations, including mutations to TP53, PTEN, or NF-1, occur in gliomas, which may profoundly affect tumor–host interactions (117, 147). Different driver mutations can co-exist; therefore, targeting of single activated pathways has led to unsuccessful therapeutic outcomes in GBM. Gain-of-function mutations of TP53 promote inflammation in GBM through upregulation of CCL2 and TNF-α expression via NFκB signaling, which consequently lead to increased infiltration of microglia and monocyte-derived immune cells in the TIME (148). NF1 loss in glioblastoma is also associated with increased macrophage infiltration displaying pro-tumorigenic features (149). Because TP53 and NF1 mutations are characteristic of the mesenchymal and proneural subtypes, respectively, it would be important to select specifically these patients in clinical trials targeting TAMs. Loss of PTEN induces increased expression of PD-L1, which correlates with PI3K expression and immune escape in GBM (150). Therefore, including PD-1/PD-L1 pathway inhibition in PTEN-mutated GBM, together with TAM targeting, could be an efficient treatment strategy, as suggested by the combinatorial effects of PI3K and CSF-1R inhibitors to reprogram macrophages toward an anti-tumorigenic phenotype (110). The recent reports identifying either a dominance of microglia or infiltrating macrophages in treatment-naïve gliomas may be due to the distinct genetic make-up of these tumors, as suggested above, and TAMs adopt distinct programming dependent on their ontogeny. Specific targeting of one or the other subsets of TAMs may thus prove to be advantageous to alleviate the protumorigenic functions of the targeted populations while maintaining the homeostatic functions of the other.
Non-small cell lung cancer (NSCLC) is characterized by driver mutations, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and KRAS, permitting the efficacy of targeted therapies [reviewed in (151)]. KRAS mutations, however, are not targetable. The immune landscape of these tumors shows increased intratumoral myeloid and T cells (152), while loss of LKB1 in KRAS-mutated NSCLC results in higher levels of CXCL7, G-CSF, and IL-6, which promote neutrophil recruitment and macrophage activation and thereby suppress T cell activity (153). In these tumors, targeting the LKB1/AMPK pathway by activating AMPK may control tumor growth through limiting myeloid cell infiltration and polarization (154). In lung tumors not harboring targetable oncogenic mutations, T cell immunotherapy has yielded partial success. These could potentially be improved by targeting myeloid cell tissue remodeling and immunosuppressive functions to enhance the efficacy of T cell immunotherapy. The association between major driver mutations in lung cancer and PD-L1 expression on myeloid cells remains debated and EGFR mutated lung tumors have been reported to display both low (155) and high (156) PD-L1 expression. Therefore, a better understanding of PD-L1 expression in specific subsets of TAMs would be useful to target these cells specifically.
The role of tissue-resident macrophages has been well-established in clearing pre-cancerous hepatocytes in the liver (157), and senescence in the liver environment can promote the anti-tumor properties of TAMs in early stages of neoplasia (51). NOTCH signaling amplification limits the anti-tumorigenic response mediated by oncogene-induced senescence via the secretion of the senescence-associated pro-inflammatory cytokines IL-1β, IL-6, and IL-8 (158). Accordingly, targeting amplified NOTCH signaling could increase anti-tumorigenic efficacy through promoting senescence surveillance by myeloid cells. Mutated NRAS in liver cancer results in increased recruitment of anti-tumorigenic TAMs through the senescence-associated secretory phenotype (SASP) and promotes CD4+ T cell-mediated clearance of liver pre-neoplastic cells (159). Similarly, amplification of mTOR in liver cancer leads to increased levels of IL-1β, which activates NF-kB, thereby driving tumor suppressive SASP and immune cell recruitment (160). Furthermore, loss of AKT in liver cancer results in decreased content of pro-tumorigenic Wnt-producing macrophages and thereby limits tumorigenesis (161). Therefore, Wnt/β-catenin targeting may inhibit tumorigenic activities of macrophages (161). Altogether, these studies suggest that generating senescence in established HCC and modulating the SASP may represent a potent approach to reprogram TAMs in liver cancer, which would need to be tailored to the type of senescence generated in the liver TIME (159).
Discussion
Targeting different subsets of macrophages instead of pan-macrophages could improve disease outcomes by hampering the pro-tumorigenic functions of specific subsets of TAMs and protecting the homeostatic properties of others (114, 136). However, this requires understanding and considering multiple features of these cells such as the following: identifying the adequate surface markers for distinguishing different macrophage subsets in specific organs, deciphering their recruitment and activation dynamics in the course of tumor progression and response to therapy, and defining the shaping they are conditioned to by the genetic make-ups of tumors. In this review, we discussed tissue-specific functions of resident macrophages under homeostatic conditions and in malignancy. We propose that tissue-resident macrophage populations should be targeted during tumor initiation, since they are often involved in early inflammatory processes and are a major contributor to the recruitment of monocyte-derived macrophages. Meanwhile, monocyte-derived macrophage subsets may be best targeted at later time points of tumor progression, since they are often involved in tumor invasiveness and immunosuppression. However, considerable work should be undertaken to better understand the contribution of TAM origin to tumor progression, which requires employing lineage-tracing studies in the context of chronically inflamed tumors in particular. The majority of macrophage-targeting approaches are focusing on CSF-1R inhibition to either deplete or reprogram macrophage populations toward an anti-tumorigenic phenotype and several studies are focusing on combining chemotherapy and immunotherapy with CSF-1R inhibitors (10, 118). However, it is still unclear whether inhibition of CSF-1R similarly affects monocyte-derived and tissue-resident macrophage subsets in different cancer types, which needs to be addressed to fully capture either the efficacy or failures of such treatments.
Importantly, the use of sophisticated mouse models closely reproducing the human genetics of tumors and composition of the TAM pool will be essential to test the efficacy and long-lasting effects of macrophage-centric therapies, as potential resistance could emerge.
Overall, we are only beginning to appreciate the potential of macrophage subset reprogramming. Rather than depleting them, re-educating TAMs into a homeostatic activation state and controlling the recruitment of immunosuppressive subsets could boost anti-tumor immunity. These novel therapeutic avenues could then hold promise for the development of effective anti-cancer treatments, particularly when used synergistically with tumor- or T cell-centric therapies.
Statements
Author contributions
KK, SV, and LA conceptualized the study. KK, LA, SV, and CR wrote the manuscript.
Funding
LA is gratefully supported by grants from the Dutch Cancer Society (KWF 10658/2016-2, KWF12049/2018-2), the NWO Vidi program (91719355), and the Brain Tumor Funders' Collaborative, and by the Oncode Institute and the Center for Cancer Genomics (CGC.nl).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
BhargavaPLeeCH. Role and function of macrophages in the metabolic syndrome. Biochem J. (2012) 442:253–62. 10.1042/BJ20111708
2.
FranklinRALiMO. Ontogeny of tumor-associated macrophages and its implication in cancer regulation. Trends Cancer. (2016) 2:20–34. 10.1016/j.trecan.2015.11.004
3.
MowatAMScottCLBainCC. Barrier-tissue macrophages: functional adaptation to environmental challenges. Nat Med. (2017) 23:1258–70. 10.1038/nm.4430
4.
GinhouxFGuilliamsM. Tissue-resident macrophage ontogeny and homeostasis. Immunity. (2016) 44:439–49. 10.1016/j.immuni.2016.02.024
5.
van FurthRCohnZAHirschJGHumphreyJHSpectorWGLangevoortHL. The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. Bull World Health Organ. (1972) 46:845–52.
6.
YonaSKimKWWolfYMildnerAVarolDBrekerMet al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. (2013) 38:79–91. 10.1016/j.immuni.2012.12.001
7.
SchulzCGomez PerdigueroEChorroLSzabo-RogersHCagnardNKierdorfKet al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science. (2012) 336:86–90. 10.1126/science.1219179
8.
HoeksemaMAde WintherMP. Epigenetic regulation of monocyte and macrophage function. Antioxid Redox Signal. (2016) 25:758–74. 10.1089/ars.2016.6695
9.
IvashkivLB. Epigenetic regulation of macrophage polarization and function. Trends Immunol. (2013) 34:216–23. 10.1016/j.it.2012.11.001
10.
DeNardoDGBrennanDJRexhepajERuffellBShiaoSLMaddenSFet al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. (2011) 1:54–67. 10.1158/2159-8274.CD-10-0028
11.
ChanmeeTOntongPKonnoKItanoN. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. (2014) 6:1670–90. 10.3390/cancers6031670
12.
TakeyaMKomoharaY. Role of tumor-associated macrophages in human malignancies: friend or foe?Pathol Int. (2016) 66:491–505. 10.1111/pin.12440
13.
PohARErnstM. Targeting macrophages in cancer: from bench to bedside. Front Oncol. (2018) 8:49. 10.3389/fonc.2018.00049
14.
QuailDFJoyceJA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. (2013) 19:1423–37. 10.1038/nm.3394
15.
Gomez PerdigueroEKlapprothKSchulzCBuschKAzzoniECrozetLet al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature. (2015) 518:547–51. 10.1038/nature13989
16.
GinhouxFGreterMLeboeufMNandiSSeePGokhanSet al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. (2010) 330:841–5. 10.1126/science.1194637
17.
KierdorfKErnyDGoldmannTSanderVSchulzCPerdigueroEGet al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci. (2013) 16:273–80. 10.1038/nn.3318
18.
SevenichL. Brain-resident microglia and blood-borne macrophages orchestrate central nervous system inflammation in neurodegenerative disorders and brain cancer. Front Immunol. (2018) 9:697. 10.3389/fimmu.2018.00697
19.
NaitoMYamamuraFNishikawaSTakahashiK. Development, differentiation, and maturation of fetal mouse yolk sac macrophages in cultures. J Leukoc Biol. (1989) 46:1–10. 10.1002/jlb.46.1.1
20.
GuilliamsMDe KleerIHenriSPostSVanhoutteLDe PrijckSet al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J Exp Med. (2013) 210:1977–92. 10.1084/jem.20131199
21.
ButovskyOJedrychowskiMPMooreCSCialicRLanserAJGabrielyGet al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat Neurosci. (2014) 17:131–43. 10.1038/nn.3599
22.
YamamotoTKaizuCKawasakiTHasegawaGUmezuHOhashiRet al. Macrophage colony-stimulating factor is indispensable for repopulation and differentiation of Kupffer cells but not for splenic red pulp macrophages in osteopetrotic (op/op) mice after macrophage depletion. Cell Tissue Res. (2008) 332:245–56. 10.1007/s00441-008-0586-8
23.
WangYSzretterKJVermiWGilfillanSRossiniCCellaMet al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol. (2012) 13:753–60. 10.1038/ni.2360
24.
ShibataYBerclazPYChroneosZCYoshidaMWhitsettJATrapnellBC. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity. (2001) 15:557–67. 10.1016/S1074-7613(01)00218-7
25.
GreterMLeliosIPelczarPHoeffelGPriceJLeboeufMet al. Stroma-derived interleukin-34 controls the development and maintenance of Langerhans cells and the maintenance of microglia. Immunity. (2012) 37:1050–60. 10.1016/j.immuni.2012.11.001
26.
ButtgereitALeliosIYuXVrohlingsMKrakoskiNRGautierELet al. Sall1 is a transcriptional regulator defining microglia identity and function. Nat Immunol. (2016) 17:1397–406. 10.1038/ni.3585
27.
KierdorfKPrinzMGeissmannFGomez PerdigueroE. Development and function of tissue resident macrophages in mice. Semin Immunol. (2015) 27:369–78. 10.1016/j.smim.2016.03.017
28.
MassEBallesterosIFarlikMHalbritterFGuntherPCrozetLet al. Specification of tissue-resident macrophages during organogenesis. Science. (2016) 353:aaf4238. 10.1126/science.aaf4238
29.
YuXButtgereitALeliosIUtzSGCanseverDBecherBet al. The cytokine TGF-beta promotes the development and homeostasis of alveolar macrophages. Immunity. (2017) 47:903–12.e4. 10.1016/j.immuni.2017.10.007
30.
SchneiderCNobsSPKurrerMRehrauerHThieleCKopfM. Induction of the nuclear receptor PPAR-gamma by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages. Nat Immunol. (2014) 15:1026–37. 10.1038/ni.3005
31.
KatsumotoALuHMirandaASRansohoffRM. Ontogeny and functions of central nervous system macrophages. J Immunol. (2014) 193:2615–21. 10.4049/jimmunol.1400716
32.
SierraAEncinasJMDeuderoJJChanceyJHEnikolopovGOverstreet-WadicheLSet al. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. Cell Stem Cell. (2010) 7:483–95. 10.1016/j.stem.2010.08.014
33.
Shigemoto-MogamiYHoshikawaKGoldmanJESekinoYSatoK. Microglia enhance neurogenesis and oligodendrogenesis in the early postnatal subventricular zone. J Neurosci. (2014) 34:2231–43. 10.1523/JNEUROSCI.1619-13.2014
34.
Labandeira-GarciaJLCosta-BesadaMALabandeiraCMVillar-ChedaBRodriguez-PerezAI. Insulin-like growth factor-1 and neuroinflammation. Front Aging Neurosci. (2017) 9:365. 10.3389/fnagi.2017.00365
35.
SebireGEmilieDWallonCHeryCDevergneODelfraissyJFet al. In vitro production of IL-6, IL-1 beta, and tumor necrosis factor-alpha by human embryonic microglial and neural cells. J Immunol. (1993) 150:1517–23.
36.
WuYDissing-OlesenLMacVicarBAStevensB. Microglia: dynamic mediators of synapse development and plasticity. Trends Immunol. (2015) 36:605–13. 10.1016/j.it.2015.08.008
37.
PaolicelliRCBolascoGPaganiFMaggiLScianniMPanzanelliPet al. Synaptic pruning by microglia is necessary for normal brain development. Science. (2011) 333:1456–8. 10.1126/science.1202529
38.
KrenkelOTackeF. Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol. (2017) 17306–21. 10.1038/nri.2017.11
39.
van der LaanLJDoppEAHaworthRPikkarainenTKangasMElomaaOet al. Regulation and functional involvement of macrophage scavenger receptor MARCO in clearance of bacteria in vivo. J Immunol. (1999) 162:939–47.
40.
KristiansenMGraversenJHJacobsenCSonneOHoffmanHJLawSKet al. Identification of the haemoglobin scavenger receptor. Nature. (2001) 409:198–201. 10.1038/35051594
41.
GordonSMartinez-PomaresL. Physiological roles of macrophages. Pflugers Arch. (2017) 469:365–74. 10.1007/s00424-017-1945-7
42.
KnollePAUhrigAProtzerUTripplerMDuchmannRMeyer zum BuschenfeldeKHet al. Interleukin-10 expression is autoregulated at the transcriptional level in human and murine Kupffer cells. Hepatology. (1998) 27:93–9. 10.1002/hep.510270116
43.
SorooshPDohertyTADuanWMehtaAKChoiHAdamsYFet al. Lung-resident tissue macrophages generate Foxp3+ regulatory T cells and promote airway tolerance. J Exp Med. (2013) 210:775–88. 10.1084/jem.20121849
44.
BissellDMWangSSJarnaginWRRollFJ. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest. (1995) 96:447–55. 10.1172/JCI118055
45.
HussellTBellTJ. Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol. (2014) 14:81–93. 10.1038/nri3600
46.
HuiXGuPZhangJNieTPanYWuDet al. Adiponectin enhances cold-induced browning of subcutaneous adipose tissue via promoting M2 macrophage proliferation. Cell Metab. (2015) 22:279–90. 10.1016/j.cmet.2015.06.004
47.
JenkinsSJRuckerlDCookPCJonesLHFinkelmanFDvan RooijenNet al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science. (2011) 332:1284–8. 10.1126/science.1204351
48.
WellensteinMDde VisserKE. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity. (2018) 48:399–416. 10.1016/j.immuni.2018.03.004
49.
ThorssonVGibbsDLBrownSDWolfDBortoneDSOu YangTHet al. The immune landscape of cancer. Immunity. (2018) 48:812–30.e14. 10.1016/j.immuni.2018.03.023
50.
VenteicherASTiroshIHebertCYizhakKNeftelCFilbinMGet al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. (2017) 355:eaai8478. 10.1126/science.aai8478
51.
LujambioAAkkariLSimonJGraceDTschaharganehDFBoldenJEet al. Non-cell-autonomous tumor suppression by p53. Cell. (2013) 153:449–60. 10.1016/j.cell.2013.03.020
52.
MeylanEDooleyALFeldserDMShenLTurkEOuyangCet al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature. (2009) 462:104–7. 10.1038/nature08462
53.
KortleverRMSodirNMWilsonCHBurkhartDLPellegrinetLBrown SwigartLet al. Myc cooperates with Ras by programming inflammation and immune suppression. Cell. (2017) 171:1301–15.e14. 10.1016/j.cell.2017.11.013
54.
SodirNMKortleverRMBarthetVJAPellegrinetLCamposTKupczakSet al. Myc instructs and maintains pancreatic adenocarcinoma phenotype. bioRxiv [Preprint]. (2019). 10.1101/556399
55.
CoffeltSBKerstenKDoornebalCWWeidenJVrijlandKHauCSet al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. (2015) 522:345–8. 10.1038/nature14282
56.
WellensteinMDCoffeltSBDuitsDEMvan MiltenburgMHSlagterMde RinkIet al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature. (2019) 572:538–42. 10.1038/s41586-019-1450-6
57.
BezziMSeitzerNIshikawaTReschkeMChenMWangGet al. Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. Nat Med. (2018) 24:165–75. 10.1038/nm.4463
58.
MeiJXiaoZGuoCPuQMaLLiuCet al. Prognostic impact of tumor-associated macrophage infiltration in non-small cell lung cancer: a systemic review and meta-analysis. Oncotarget. (2016) 7:34217–28. 10.18632/oncotarget.9079
59.
CapeceDFischiettiMVerzellaDGaggianoACicciarelliGTessitoreAet al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. (2013) 2013:187204. 10.1155/2013/187204
60.
BowmanRLKlemmFAkkariLPyonteckSMSevenichLQuailDFet al. Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep. (2016) 17:2445–59. 10.1016/j.celrep.2016.10.052
61.
WattersJJSchartnerJMBadieB. Microglia function in brain tumors. J Neurosci Res. (2005) 81:447–55. 10.1002/jnr.20485
62.
KomoharaYOhnishiKKuratsuJTakeyaM. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. (2008) 216:15–24. 10.1002/path.2370
63.
ConiglioSJEugeninEDobrenisKStanleyERWestBLSymonsMHet al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med. (2012) 18:519–27. 10.2119/molmed.2011.00217
64.
CarusALadekarlMHagerHPilegaardHNielsenPSDonskovF. Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome. Lung Cancer. (2013) 81:130–7. 10.1016/j.lungcan.2013.03.003
65.
HirayamaSIshiiGNagaiKOnoSKojimaMYamauchiCet al. Prognostic impact of CD204-positive macrophages in lung squamous cell carcinoma: possible contribution of Cd204-positive macrophages to the tumor-promoting microenvironment. J Thorac Oncol. (2012) 7:1790–7. 10.1097/JTO.0b013e3182745968
66.
DaiFLiuLCheGYuNPuQZhangSet al. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer. (2010) 10:220. 10.1186/1471-2407-10-220
67.
OhriCMShikotraAGreenRHWallerDABraddingP. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J. (2009) 33:118–26. 10.1183/09031936.00065708
68.
KimDWMinHSLeeKHKimYJOhDYJeonYKet al. High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer. (2008) 98:1118–24. 10.1038/sj.bjc.6604256
69.
JackuteJZemaitisMPranysDSitkauskieneBMiliauskasSVaitkieneSet al. Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer. BMC Immunol. (2018) 19:3. 10.1186/s12865-018-0241-4
70.
ChenJJYaoPLYuanAHongTMShunCTKuoMLet al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. (2003) 9:729–37.
71.
TakanamiITakeuchiKKodairaS. Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology. (1999) 57:138–42. 10.1159/000012021
72.
PikarskyEPoratRMSteinIAbramovitchRAmitSKasemSet al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. (2004) 431:461–6. 10.1038/nature02924
73.
MantovaniASozzaniSLocatiMAllavenaPSicaA. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. (2002) 23:549–55. 10.1016/S1471-4906(02)02302-5
74.
JuCTackeF. Hepatic macrophages in homeostasis and liver diseases: From pathogenesis to novel therapeutic strategies. Cell Mol Immunol. (2016) 13:316–27. 10.1038/cmi.2015.104
75.
WanSKuoNKryczekIZouWWellingTH. Myeloid cells in hepatocellular carcinoma. Hepatology. (2015) 62:1304–12. 10.1002/hep.27867
76.
LimSYYuzhalinAEGordon-WeeksANMuschelRJ. Tumor-infiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells. Oncogene. (2016) 35:5735–45. 10.1038/onc.2016.107
77.
KitamuraTQianBZPollardJW. Immune cell promotion of metastasis. Nat Rev Immunol. (2015) 15:73–86. 10.1038/nri3789
78.
YaoRRLiJHZhangRChenRXWangYH. M2-polarized tumor-associated macrophages facilitated migration and epithelial–mesenchymal transition of HCC cells via the TLR4/STAT3 signaling pathway. World J Surg Oncol. (2018) 16:9. 10.1186/s12957-018-1312-y
79.
BeaverLMStemmyEJSchwartzAMDamskerJMConstantSLCeryakSMet al. Lung inflammation, injury, and proliferative response after repetitive particulate hexavalent chromium exposure. Environ Health Perspect. (2009) 117:1896–902. 10.1289/ehp.0900715
80.
van EedenSFTanWCSuwaTMukaeHTerashimaTFujiiTet al. Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM(10)). Am J Respir Crit Care Med. (2001) 164:826–30. 10.1164/ajrccm.164.5.2010160
81.
HamiltonGRathBKlamethLHochmairMJ. Small cell lung cancer: Recruitment of macrophages by circulating tumor cells. Oncoimmunology. (2016) 5:e1093277. 10.1080/2162402X.2015.1093277
82.
YuLXLingYWangHY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol. (2018) 2:6. 10.1038/s41698-018-0048-z
83.
DixonLJBarnesMTangHPritchardMTNagyLE. Kupffer cells in the liver. Compr Physiol. (2013) 3:785–97. 10.1002/cphy.c120026
84.
WuSYWatabeK. The roles of microglia/macrophages in tumor progression of brain cancer and metastatic disease. Front Biosci. (2017) 22:1805–29. 10.2741/4573
85.
HambardzumyanDGutmannDHKettenmannH. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. (2016) 19:20–7. 10.1038/nn.4185
86.
ShaftelSSCarlsonTJOlschowkaJAKyrkanidesSMatousekSBO'BanionMK. Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J Neurosci. (2007) 27:9301–9. 10.1523/JNEUROSCI.1418-07.2007
87.
WangSCHongJHHsuehCChiangCS. Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model. Lab Invest. (2012) 92:151–62. 10.1038/labinvest.2011.128
88.
KuMCWolfSARespondekDMatyashVPohlmannAWaicziesSet al. GDNF mediates glioblastoma-induced microglia attraction but not astrogliosis. Acta Neuropathol. (2013) 125:609–20. 10.1007/s00401-013-1079-8
89.
Held-FeindtJHattermannKMuerkosterSSWedderkoppHKnerlich-LukoschusFUngefrorenHet al. CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs). Exp Cell Res. (2010) 316:1553–66. 10.1016/j.yexcr.2010.02.018
90.
LeungSYWongMPChungLPChanASYuenST. Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol. (1997) 93:518–27. 10.1007/s004010050647
91.
ZhangJSarkarSCuaRZhouYHaderWYongVW. A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis. Carcinogenesis. (2012) 33:312–9. 10.1093/carcin/bgr289
92.
HambardzumyanDSquatritoMHollandEC. Radiation resistance and stem-like cells in brain tumors. Cancer Cell. (2006) 10:454–6. 10.1016/j.ccr.2006.11.008
93.
ZhouWKeSQHuangZFlavahanWFangXPaulJet al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. (2015) 17:170–82. 10.1038/ncb3090
94.
YeXZXuSLXinYHYuSCPingYFChenLet al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-beta1 signaling pathway. J Immunol. (2012) 189:444–53. 10.4049/jimmunol.1103248
95.
DasASinhaMDattaSAbasMChaffeeSSenCKet al. Monocyte and macrophage plasticity in tissue repair and regeneration. Am J Pathol. (2015) 185:2596–606. 10.1016/j.ajpath.2015.06.001
96.
McQuattie-PimentelACBudingerGRSBallingerMN. Monocyte-derived alveolar macrophages: the dark side of lung repair?Am J Respir Cell Mol Biol. (2018) 58:5–6. 10.1165/rcmb.2017-0328ED
97.
Cortez-RetamozoVEtzrodtMNewtonARauchPJChudnovskiyABergerCet al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci USA. (2012) 109:2491–6. 10.1073/pnas.1113744109
98.
LaouiDVan OvermeireEDi ConzaGAldeniCKeirsseJMoriasYet al. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res. (2014) 74:24–30. 10.1158/0008-5472.CAN-13-1196
99.
DesaiTJBrownfieldDGKrasnowMA. Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature. (2014) 507:190–4. 10.1038/nature12930
100.
ScottCLT'JonckWMartensLTodorovHSichienDSoenBet al. The transcription factor ZEB2 is required to maintain the tissue-specific identities of macrophages. Immunity. (2018) 49:312–25.e5. 10.1016/j.immuni.2018.07.004
101.
BeattieLSawtellAMannJFrameTCMTealBde Labastida RiveraFet al. Bone marrow-derived and resident liver macrophages display unique transcriptomic signatures but similar biological functions. J Hepatol. (2016) 65:758–68. 10.1016/j.jhep.2016.05.037
102.
WuJLiJSalcedoRMivechiNFTrinchieriGHoruzskoA. The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res. (2012) 72:3977–86. 10.1158/0008-5472.CAN-12-0938
103.
DingTXuJWangFShiMZhangYLiSPet al. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol. (2009) 40:381–9. 10.1016/j.humpath.2008.08.011
104.
Makarova-RusherOVMedina-EcheverzJDuffyAGGretenTF. The yin and yang of evasion and immune activation in HCC. J Hepatol. (2015) 62:1420–9. 10.1016/j.jhep.2015.02.038
105.
ScottCLZhengFDe BaetselierPMartensLSaeysYDe PrijckSet al. Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nat Commun. (2016) 7:10321. 10.1038/ncomms10321
106.
BadieBSchartnerJM. Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery. (2000) 46:957–61. 10.1227/00006123-200004000-00035
107.
MullerABrandenburgSTurkowskiKMullerSVajkoczyP. Resident microglia, and not peripheral macrophages, are the main source of brain tumor mononuclear cells. Int J Cancer. (2015) 137:278–88. 10.1002/ijc.29379
108.
DuffieldJSForbesSJConstandinouCMClaySPartolinaMVuthooriSet al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest. (2005) 115:56–65. 10.1172/JCI200522675
109.
ChenZFengXHertingCJGarciaVANieKPongWWet al. Cellular and molecular identity of tumor-associated macrophages in glioblastoma. Cancer Res. (2017) 77:2266–78. 10.1158/0008-5472.CAN-16-2310
110.
QuailDFJoyceJA. Molecular pathways: deciphering mechanisms of resistance to macrophage-targeted therapies. Clin Cancer Res. (2017) 23:876–84. 10.1158/1078-0432.CCR-16-0133
111.
ShiraishiDFujiwaraYHorladHSaitoYIrikiTTsubokiJet al. CD163 is required for protumoral activation of macrophages in human and murine sarcoma. Cancer Res. (2018) 78:3255–66. 10.1158/0008-5472.CAN-17-2011
112.
EtzerodtATsalkitziKManieckiMDamskyWDelfiniMBaudoinEet al. Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression. J Exp Med. (2019). 10.1084/jem.20182124. [Epub ahead of print].
113.
RiesCHCannarileMAHovesSBenzJWarthaKRunzaVet al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. (2014) 25:846–59. 10.1016/j.ccr.2014.05.016
114.
PyonteckSMAkkariLSchuhmacherAJBowmanRLSevenichLQuailDFet al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. (2013) 19:1264–72. 10.1038/nm.3337
115.
QuailDFBowmanRLAkkariLQuickMLSchuhmacherAJHuseJTet al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. (2016) 352:aad3018. 10.1126/science.aad3018
116.
ButowskiNColmanHDe GrootJFOmuroAMNayakLWenPYet al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an ivy foundation early phase clinical trials consortium phase ii study. Neuro Oncol. (2016) 18:557–64. 10.1093/neuonc/nov245
117.
BrennanCWVerhaakRGMcKennaACamposBNoushmehrHSalamaSRet al. The somatic genomic landscape of glioblastoma. Cell. (2013) 155:462–77. 10.1016/j.cell.2013.09.034
118.
StrachanDCRuffellBOeiYBissellMJCoussensLMPryerNet al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells. Oncoimmunology. (2013) 2:e26968. 10.4161/onci.26968
119.
XuJEscamillaJMokSDavidJPricemanSWestBet al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. (2013) 73:2782–94. 10.1158/0008-5472.CAN-12-3981
120.
MacDonaldKPPalmerJSCronauSSeppanenEOlverSRaffeltNCet al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood. (2010) 116:3955–63. 10.1182/blood-2010-02-266296
121.
BoimelPJSmirnovaTZhouZNWyckoffJParkHConiglioSJet al. Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast Cancer Res. (2012) 14:R23. 10.1186/bcr3108
122.
Sanchez-MartinLEstechaASamaniegoRSanchez-RamonSVegaMASanchez-MateosP. The chemokine CXCL12 regulates monocyte–macrophage differentiation and RUNX3 expression. Blood. (2011) 117:88–97. 10.1182/blood-2009-12-258186
123.
LimSYYuzhalinAEGordon-WeeksANMuschelRJ. Targeting the CCL2–CCR2 signaling axis in cancer metastasis. Oncotarget. (2016) 7:28697–710. 10.18632/oncotarget.7376
124.
DeshmaneSLKremlevSAminiSSawayaBE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. (2009) 29:313–26. 10.1089/jir.2008.0027
125.
QianBZLiJZhangHKitamuraTZhangJCampionLRet al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. (2011) 475:222–5. 10.1038/nature10138
126.
BonapaceLCoissieuxMMWyckoffJMertzKDVargaZJuntTet al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. (2014) 515:130–3. 10.1038/nature13862
127.
ChengALKangYKChenZTsaoCJQinSKimJSet al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. (2009) 10:25–34. 10.1016/S1470-2045(08)70285-7
128.
BruixJQinSMerlePGranitoAHuangYHBodokyGet al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. (2017) 389:56–66. 10.1016/S0140-6736(16)32453-9
129.
PientaKJMachielsJPSchrijversDAlekseevBShkolnikMCrabbSJet al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs. (2013) 31:760–8. 10.1007/s10637-012-9869-8
130.
BajorDLXuXTorigianDAMickRGarciaLRRichmanLPet al. Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. Cancer Immunol Res. (2014) 2:1051–8. 10.1158/2326-6066.CIR-14-0154
131.
BranaICallesALoRussoPMYeeLKPuchalskiTASeetharamSet al. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol. (2015) 10:111–23. 10.1007/s11523-014-0320-2
132.
RiesCHHovesSCannarileMARuttingerD. CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. Curr Opin Pharmacol. (2015) 23:45–51. 10.1016/j.coph.2015.05.008
133.
PatwardhanPPSurrigaOBeckmanMJde StanchinaEDematteoRPTapWDet al. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin Cancer Res. (2014) 20:3146–58. 10.1158/1078-0432.CCR-13-2576
134.
MokSTsoiJKoyaRCHu-LieskovanSWestBLBollagGet al. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer. (2015) 15:356. 10.1186/s12885-015-1377-8
135.
YanDKowalJAkkariLSchuhmacherAJHuseJTWestBLet al. Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas. Oncogene. (2017) 36:6049–58. 10.1038/onc.2017.261
136.
KloepperJRiedemannLAmoozgarZSeanoGSusekKYuVet al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci USA. (2016) 113:4476–81. 10.1073/pnas.1525360113
137.
OlsonOCKimHQuailDFFoleyEAJoyceJA. Tumor-associated macrophages suppress the cytotoxic activity of antimitotic agents. Cell Rep. (2017) 19:101–13. 10.1016/j.celrep.2017.03.038
138.
ByrneKTVonderheideRH. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep. (2016) 15:2719–32. 10.1016/j.celrep.2016.05.058
139.
VonderheideRHBurgJMMickRTroskoJALiDShaikMNet al. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. (2013) 2:e23033. 10.4161/onci.23033
140.
CannarileMAWeisserMJacobWJeggAMRiesCHRuttingerD. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. (2017) 5:53. 10.1186/s40425-017-0257-y
141.
BarkerHEPagetJTKhanAAHarringtonKJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. (2015) 15:409–25. 10.1038/nrc3958
142.
TsaiCSChenFHWangCCHuangHLJungSMWuCJet al. Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int J Radiat Oncol Biol Phys. (2007) 68:499–507. 10.1016/j.ijrobp.2007.01.041
143.
MengYBeckettMALiangHMauceriHJvan RooijenNCohenKSet al. Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res. (2010) 70:1534–43. 10.1158/0008-5472.CAN-09-2995
144.
StaffordJHHiraiTDengLChernikovaSBUrataKWestBLet al. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. Neuro Oncol. (2016) 18:797–806. 10.1093/neuonc/nov272
145.
KalbasiAKomarCTookerGMLiuMLeeJWGladneyWLet al. Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma. Clin Cancer Res. (2017) 23:137–48. 10.1158/1078-0432.CCR-16-0870
146.
EneCIHollandEC. Personalized medicine for gliomas. Surg Neurol Int. (2015) 6:S89–95. 10.4103/2152-7806.151351
147.
Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. (2008) 455:1061–8. 10.1038/nature07385
148.
HamSWJeonHYJinXKimEJKimJKShinYJet al. TP53 gain-of-function mutation promotes inflammation in glioblastoma. Cell Death Differ. (2018) 26:409–25. 10.1038/s41418-018-0126-3
149.
WangQHuBHuXKimHSquatritoMScarpaceLet al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. (2017) 32:42–56.e6. 10.1016/j.ccell.2017.06.003
150.
XueSHuMIyerVYuJ. Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. J Hematol Oncol. (2017) 10:81. 10.1186/s13045-017-0455-6
151.
HirschFRScagliottiGVMulshineJLKwonRCurranWJJrWuYLet al. Lung cancer: current therapies and new targeted treatments. Lancet. (2017) 389:299–311. 10.1016/S0140-6736(16)30958-8
152.
BuschSEHankeMLKarglJMetzHEMacPhersonDHoughtonAM. Lung cancer subtypes generate unique immune responses. J Immunol. (2016) 197:4493–503. 10.4049/jimmunol.1600576
153.
KoyamaSAkbayEALiYYArefARSkoulidisFHerter-SprieGSet al. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. (2016) 76:999–1008. 10.1158/0008-5472.CAN-15-1439
154.
KhanASFrigoDE. A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer. Nat Rev Urol. (2017) 14:164–80. 10.1038/nrurol.2016.272
155.
ChaYJKimHRLeeCYChoBCShimHS. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer. (2016) 97:73–80. 10.1016/j.lungcan.2016.05.001
156.
AkbayEAKoyamaSCarreteroJAltabefATchaichaJHChristensenCLet al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. (2013) 3:1355–63. 10.1158/1535-7163.TARG-13-B290
157.
EggertTGretenTF. Tumor regulation of the tissue environment in the liver. Pharmacol Ther. (2017) 173:47–57. 10.1016/j.pharmthera.2017.02.005
158.
HoareMItoYKangTWWeekesMPMathesonNJPattenDAet al. NOTCH1 mediates a switch between two distinct secretomes during senescence. Nat Cell Biol. (2016) 18:979–92. 10.1038/ncb3397
159.
KangTWYevsaTWollerNHoenickeLWuestefeldTDauchDet al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. (2011) 479:547–51. 10.1038/nature10599
160.
LabergeRMSunYOrjaloAVPatilCKFreundAZhouLet al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol. (2015) 17:1049–61. 10.1038/ncb3195
161.
DebebeAMedinaVChenCYMahajanIMJiaCFuDet al. Wnt/beta-catenin activation and macrophage induction during liver cancer development following steatosis. Oncogene. (2017) 36:6020–9. 10.1038/onc.2017.207
Summary
Keywords
macrophages, tumor immune microenvironment, solid tumors, immune phenotype, macrophage plasticity
Citation
Kielbassa K, Vegna S, Ramirez C and Akkari L (2019) Understanding the Origin and Diversity of Macrophages to Tailor Their Targeting in Solid Cancers. Front. Immunol. 10:2215. doi: 10.3389/fimmu.2019.02215
Received
30 July 2019
Accepted
02 September 2019
Published
25 September 2019
Volume
10 - 2019
Edited by
Zhihai Qin, Institute of Biophysics (CAS), China
Reviewed by
Limin Zheng, Sun Yat-sen University, China; Yoshihiro Komohara, Kumamoto University, Japan
Updates
Copyright
© 2019 Kielbassa, Vegna, Ramirez and Akkari.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Leila Akkari l.akkari@nki.nl
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.